文献速递瓣膜外科

猪生物瓣主动脉瓣置换术后早期抗凝随机对照试验(ANTIPRO)

Early anticoagulation after aortic valve replacement with porcine bioprosthesis randomized control trial (ANTIPRO).
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

这项前瞻性随机开放标签试验在2个心脏外科中心连续纳入140例猪生物瓣主动脉瓣置换术后患者,抗凝组接受华法林+阿司匹林,对照组仅用阿司匹林。1年时两组平均跨瓣压差相似(对照组18.6 mmHg vs 抗凝组18.1 mmHg,P=0.701),功能分级及次要结局均无差异。

要点

  • 抗凝组1年平均跨瓣压差18.1 mmHg,对照组18.6 mmHg,两组相似(P=0.701)。
  • 3个月和1年功能分级在两组间无差异。
  • 出血、栓塞事件及瓣周漏等次要结局在两组间无差异。

核心结论

  • 在抗血小板治疗基础上加用3个月口服抗凝未检测到对主动脉瓣置换术后1年生物瓣血流动力学或功能分级的影响。
  • 抗凝未导致更高的并发症发生率。

研究设计与样本

  • 前瞻性、随机、开放标签试验,在2个心脏外科中心开展,连续纳入所有接受猪生物瓣主动脉瓣置换术的患者。
  • 共140例参与者,抗凝组71例接受华法林+阿司匹林,对照组69例仅接受阿司匹林。
  • 总体人群平均年龄72.4岁(SD:7.1),全局EuroSCORE为7.65(SD:5.73)。
  • 主要结局为主动脉瓣置换术后1年平均跨瓣压差和纽约心脏协会(NYHA)分级变化;次要结局为严重及轻微出血、栓塞事件和人工瓣膜漏。

主要发现

  • 1年时平均跨瓣压差在对照组为18.6 mmHg(SD:1.1),在抗凝组为18.1 mmHg(SD:1.0),两组相似(P=0.701)。
  • 3个月或1年时功能分级在组间未发现差异。
  • 次要结局在组间未发现差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Most evidence for anticoagulation (AC) in aortic bioprosthesis is centred on embolic events, bleeding and reintervention risk. The effect of AC on haemodynamics has not been previously assessed. Our hypothesis was that patients with early AC after aortic valve replacement (AVR) with porcine bioprosthesis have better haemodynamics at 1 year of follow-up. METHODS: Prospective, randomized, open-label trial conducted at 2 cardiac surgery centres. All patients undergoing AVR with porcine bioprosthesis were consecutively recruited. The anticoagulated group received warfarin + aspirin and the non-anticoagulated (control) only aspirin. The primary outcome was mean gradient after 1 year of AVR and change in New York Heart Association class. Secondary outcomes were major and minor bleeding, embolic events and prosthetic leak. RESULTS: Of 140 participants in the study, 71 were assigned to the anticoagulated group and 69 to the control group. The mean age of the overall population was 72.4 (SD: 7.1) years. Global EuroSCORE was 7.65 (SD: 5.73). At 1 year, the mean gradient was similar between both groups [18.6 (SD: 1.1 mmHg) and 18.1 (SD: 1.0 mmHg) in the control and anticoagulated groups, respectively, P = 0.701]. No differences in functional class at 3 months or 1 year were found among groups. No differences were found among groups in the secondary outcomes. CONCLUSIONS: The addition of 3 months of oral AC to anti-aggregation treatment was not detected to affect bioprosthetic haemodynamics nor functional class at 1 year after AVR. Likewise, AC does not lead to the higher incidence of complications.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Fernandez A, Loza G, Parma G, et al. Early anticoagulation after aortic valve replacement with porcine bioprosthesis randomized control trial (ANTIPRO). Eur J Cardiothorac Surg. 2022. PMID: 36308446. doi:10.1093/ejcts/ezac507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。